· PDUFA target date set for December 19 by the FDA · Runway significantly extended Lund, Sweden, 23 April 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced its interim report January-March 2026. Read more…
Use of numares’ metabolite constellation showed a stable urinary metabolic profile in the first 14 days for living donor recipients, enabling accurate early rejection detection Deceased donor recipients exhibit ischemia‑driven metabolic alterations that transiently mask rejection signals Groundbreaking study was led by researchers at University Hospital Regensburg in conjunction with numares Health Regensburg, Germany, 09 […]
Lund, Sweden, 29 October 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced that it will host a virtual event featuring two distinguished transplant surgeons; Professor Robert Montgomery from NYU Langone Transplant Institute and Professor Matthew Cooper from the Medical College of Wisconsin, to provide deeper insights into the medical journey of highly sensitized […]
